15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $6M | -$71M | 73.7% | -1536.9% | -$84M | $20M | $78M |
| 2024 | — | $64M | — | — | -$58M | $19M | $23M |
| 2023 | $4M | $54M | 0.0% | -1346.7% | -$37M | — | $14M |
| 2022 | $1M | -$40M | 0.0% | -3600.8% | -$44M | — | $14M |
| 2021 | $3M | -$85M | 0.0% | -2994.5% | -$70M | — | $33M |
| 2020 | $10M | -$84M | 0.0% | -814.2% | -$36M | — | $13M |
| 2019 | — | -$76M | — | — | -$69M | — | $129M |
| 2018 | $3M | -$57M | 0.0% | -1940.2% | -$48M | — | $19M |
| 2017 | $837000 | -$27M | 0.0% | -3325.7% | -$24M | — | $138M |
| 2016 | — | -$22M | — | — | -$14M | — | $69M |
| 2015 | — | -$15M | — | — | — | — | $40M |
| 2014 | — | -$27M | — | — | — | — | $12M |
| 2013 | — | $4M | — | — | -$1000 | — | $424000 |
| 2012 | — | -$11M | — | — | -$4M | — | $396000 |
| 2011 | — | -$3M | — | — | -$8M | — | $2M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $9M | -$17M | 69.1% | -264.1% | -$21M | $18M | $61M |
| Dec '25 | $5M | -$20M | 80.7% | -422.7% | -$19M | $20M | $78M |
| Sep '25 | $0 | -$5M | — | — | -$24M | $20M | $83M |
| Jun '25 | $400000 | $109M | 0.0% | -5698.0% | -$22M | $20M | $164M |
| Mar '25 | — | -$12M | — | — | -$20M | $19M | $16M |
| Dec '24 | — | -$9M | — | — | -$17M | $19M | $23M |
| Sep '24 | — | -$30M | — | — | -$13M | $19M | $16M |
| Jun '24 | — | $7M | — | — | -$13M | $18M | $34M |
| Mar '24 | — | -$32M | — | — | -$15M | $18M | $18M |
| Dec '23 | $0 | -$17M | — | — | -$9M | — | $14M |
| Sep '23 | $0 | -$12M | — | — | -$6M | — | $5M |
| Jun '23 | $4M | -$17M | 0.0% | -301.5% | -$10M | — | $6M |
| Mar '23 | — | -$9M | — | — | -$12M | — | $5M |
| Dec '22 | $68000 | -$7M | 0.0% | -19023.5% | -$14M | — | $14M |
| Sep '22 | $0 | -$6M | — | — | -$7M | — | $6M |
| Jun '22 | $1M | -$4M | 0.0% | -800.8% | -$9M | — | $6M |
| Mar '22 | $346000 | -$22M | 0.0% | -5951.2% | -$14M | — | $20M |
| Dec '21 | — | -$47M | — | — | -$34M | — | $33M |
| Sep '21 | — | -$7M | — | — | -$11M | — | $44M |
| Jun '21 | — | -$15M | — | — | -$12M | — | $27M |
How the market has priced ABEO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Abeona Therapeutics Inc.'s revenue has declined 10.3% per year. These are computed facts, not advice.
As of FY2025, Abeona Therapeutics Inc. reported $20M of total debt against $78M of cash; operating income covered interest expense -23.9×.
In FY2025, gross margin was 73.7%, operating margin -1536.9%, and net margin -1223.1%.
As of Jun '26, Abeona Therapeutics Inc. traded at a price-to-earnings ratio of about 4.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.